| 2005 |
- October 1, Sumitomo Dainippon Pharma created.
|
| 2006 |
-
AmBisome® (therapeutic agent for systemic fungal
infection) launched in Japan.
|
| 2007 |
-
The laboratory products business was transferred to DS
Pharma Biomedical Co., Ltd.
- Mid-term Business Plan (FY2007-FY2009) drawn up.
|
| 2008 |
-
LONASEN® (atypical antipsychotic) launched in Japan.
-
AVAPRO® (therapeutic agent for hypertension) launched
in Japan.
|
| 2009 |
-
TRERIEF® (Parkinson's disease
drug) launched in Japan.
-
Dainippon Sumitomo Pharma America Holdings, Inc.
(currently, Sumitomo Pharma America, Inc.) established in
the U.S. as a holding company.
-
Acquired Sepracor Inc. (currently, Sumitomo Pharma
America, Inc.), which became a wholly owned subsidiary of
the U.S. holdings company.
|
| 2010 |
-
MIRIPLA® (therapeutic agent for hepatocellular
carcinoma) launched in Japan.
-
Second Mid-term Business Plan (FY2010-FY2012) drawn up.
-
Sepracor Inc. (currently, Sumitomo Pharma America, Inc.)
and Dainippon Sumitomo Pharma America, Inc. merged.
-
METGLUCO® (biguanide oral hypoglycemic) launched in
Japan.
- Growth hormone business transferred.
-
Animal Health Products business split off to establish DS
Pharma Animal Health Co., Ltd.
|
| 2011 |
-
LATUDA® (atypical antipsychotic) launched in the U.S.
by Sunovion Pharmaceuticals Inc. (currently, Sumitomo
Pharma America, Inc.)
-
SUREPOST® (rapid-acting insulin secretagogue) launched
in Japan.
|
| 2012 |
- Acquired Boston Biomedical, Inc.
-
Sunovion Pharmaceuticals Inc. (currently, Sumitomo Pharma
America, Inc.) acquired Elevation Pharmaceuticals,
Inc.
-
AIMIX® (therapeutic agent for hypertension) launched
in Japan.
|
| 2013 |
-
Sunovion Pharmaceuticals Asia Pacific Pte Ltd. (currently,
Sumitomo Pharma Asia Pacific Pte. Ltd.) established as a
subsidiary in Singapore.
-
Third Mid-term Business Plan (FY2013-FY2017) drawn up.
-
Boston Biomedical Pharma, Inc. established in the U.S. as
a subsidiary focusing on sales of anti-cancer drugs.
|
| 2014 |
-
Joint venture company, Sighregen Co., Ltd. established.
-
Kobe Regenerative & Cellular Medicine Center
(currently, Regenerative & Cellular Medicine Kobe
Center) opened.
 Regenerative & Cellular Medicine Kobe Center
-
APTIOM® (antiepileptic) launched in the U.S. by
Sunovion Pharmaceuticals Inc. (currently, Sumitomo Pharma
America, Inc.)
-
LATUDA® (atypical antipsychotic) launched in the U.K.
by Sunovion Pharmaceuticals Europe Ltd.
|
| 2015 |
-
Started promotion of REMITCH® with indication for
pruritus in chronic liver disease patients.
|
| 2016 |
-
Sunovion Pharmaceuticals Inc. (currently, Sumitomo Pharma
America, Inc.) acquired Cynapsus Therapeutics Inc., a
Canadian company.
-
DS Pharma Promo Co., Ltd. (currently, Sumitomo Pharma
Promo Co., Ltd.) established as a subsidiary for promoting
authorized generics etc.
|
| 2017 |
- Acquired Tolero Pharmaceuticals, Inc.
-
Boston Biomedical Pharma, Inc. integrated into its
subsidiary Boston Biomedical, Inc. and corporate name
changed to Boston Biomedical, Inc.
|
| 2018 |
-
LONASEN® (atypical antipsychotic) launched in China by
Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (currently,
Sumitomo Pharma (Suzhou) Co., Ltd.)
-
Manufacturing Plant for Regenerative Medicine & Cell
Therapy (SMaRT) completed.
-
LONHALA® MAGNAIR® (therapeutic agent for COPD)
launched in the U.S. by Sunovion Pharmaceuticals Inc.
(currently, Sumitomo Pharma America, Inc.)
|
| 2019 |
- Reorganized product sites from 4 sites to 2 sites.
-
The in-vitro diagnostics business of DS Pharma Biomedical
Co., Ltd. is succeeded by a joint venture company and
consolidated with DS Pharma Promo Co., Ltd. (currently,
Sumitomo Pharma Promo Co., Ltd.)
-
Established a subsidiary, Sumitomo Pharmaceuticals
(Thailand) Co., Ltd. (currently, Sumitomo Pharma
(Thailand) Co., Ltd.) in Thailand.
-
Mid-term Business Plan 2022 (FY2018-FY2022) drawn up.
-
RETHIO® (conditioning treatment prior to autologous
hematopoietic stem cell transplantation) launched in
Japan.
-
Started sales of Equa® and EquMet® (therapeutic
agent for type 2 diabetes) in Japan.
-
LATUDA® (atypical antipsychotic) launched in China by
Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (currently,
Sumitomo Pharma (Suzhou) Co., Ltd.)
-
LONASEN® Tape (atypical antipsychotic) launched in
Japan.
-
With the signing of a strategic alliance agreement with
Roivant Sciences, a U.S. subsidiary Sumitovant Biopharma
was established to hold shares of Myovant Sciences,
Urovant Sciences, Enzyvant Therapeutics, Altavant
Sciences, and Spirovant Sciences.
|
| 2020 |
-
LATUDA® (atypical antipsychotic) launched in Japan.
-
Boston Biomedical, Inc. and Tolero Pharmaceuticals, Inc.
integrated and corporate name changed to Sumitomo
Dainippon Pharma Oncology, Inc. (currently, Sumitomo
Pharma America, Inc.)
-
Joint venture company (S-RACMO Co., Ltd.) for CDMO
Business in the field of Regenerative Medicine and Cell
Therapy established.
-
A subsidiary, Sumitomo Pharmaceuticals Taiwan Co., Ltd.
(currently, Sumitomo Pharma Taiwan Co., Ltd.) established
in Taiwan.
-
KYNMOBI® launched in the U.S. by Sunovion
Pharmaceuticals Inc. (currently, Sumitomo Pharma America,
Inc.)
|
| 2021 |
-
ORGOVYX® (therapeutic agent for advanced prostate
cancer) launched in the U.S. by Myovant Sciences Ltd.
(currently, Sumitomo Pharma America, Inc.)
-
Sumitovant Biopharma Ltd. made Urovant Sciences Ltd., a
U.S. consolidated subsidiary, its wholly-owned subsidiary.
-
GEMTESA® (therapeutic agent for overactive bladder
(OAB)) launched in the U.S. by Urovant Sciences Ltd.
(currently, Sumitomo Pharma America, Inc.)
-
Transferred shares of Sunovion Pharmaceuticals Europe Ltd.
-
MYFEMBREE® (therapeutic agent for uterine fibroids)
launched in the U.S. by Myovant Sciences Ltd. (currently,
Sumitomo Pharma America, Inc.)
-
TWYMEEG® (therapeutic agent for type 2 diabetes)
launched in Japan.
-
Entered into an agreement for joint development and
commercialization in Psychiatry and Neurology area with
Otsuka Pharmaceutical Co., Ltd.
-
A subsidiary (Sumitomo Pharma Malaysia Sdn. Bhd.)
established in Malaysia.
|
| 2022 |
-
Sumitomo Dainippon Pharma Co., Ltd. changed its company
name to Sumitomo Pharma Co., Ltd.
-
RYTHYMIC® (cultured thymus tissue for pediatric
congenital athymia) launched in the U.S. by Enzyvant
Therapeutics Ltd. (currently, Sumitomo Pharma America,
Inc.)
-
Started promotion for Agalsidase Beta BS I.V. Infusion
[JCR] (therapeutic agent for Fabry disease) in Japan.
|
| 2023 |
-
Sumitomo Pharma Food & Chemical Co., Ltd. transferred.
-
Sumitomo Pharma Animal Health Co., Ltd. transferred.
-
Started co-promotion for IZCARGO® (recombinant
therapeutic for mucopolysaccharidosis type II) in Japan.
-
Mid-term Business Plan 2027 (FY2023-FY2027) drawn up.
-
Combined Group companies in the U.S. and Sumitomo Pharma
America, Inc. launched.
|
| 2024 |
-
Entered into an amendment agreement for joint development
and commercialization in Psychiatry and Neurology area
with Otsuka Pharmaceutical Co., Ltd.
-
The establishment of RACTHERA Co., Ltd., a joint venture
with Sumitomo Chemical Co., Ltd. for the regenerative
medicine and cell therapy business.
|
| 2025 |
-
Started co-promotion for XEPLION® and XEPLION TRI®
(long-acting antipsychotic medication) in Japan.
-
Started co-promotion for Ozempic® (therapeutic agent for
type 2 diabetes)in Japan.
-
The Asian business was transferred to Marubeni
Pharmaceuticals Corporation, a joint venture established
with Marubeni Global Pharma Corporation.
-
Started co-promotion for Wegovy® (GLP-1 receptor agonist
indicated for the treatment of obesity disease) in Japan.
|
| 2026 |
-
AMCHEPRY® (allogeneic iPS cell-derived dopaminergic neural
progenitor cell product for Parkinson's disease) received
conditional and time-limited approval in Japan.
|